Results 201 to 210 of about 29,485 (291)

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract INTRODUCTION A subset of Alzheimer's disease (AD) patients exhibits a procoagulant state that remains undiagnosed despite available treatments. We developed positron emission tomography (PET) strategies to in vivo detect cerebral microthrombi in TgCRND8 mice. METHODS PET was performed with a fibrin‐binding probe (FBP) in TgCRND8 and wild‐type
Carlos Ceron, Marta Casquero‐Veiga, Nicolás Lamanna‐Rama, Irene Fernández‐Nueda, Alberto Fernández‐Pena, Nancy Olazagoitia, Gorka Sobrino, Aitor Herraiz, María Isabel González, María Muñoz‐Hernando, Alejandro Ruperti‐Repilado, Eduardo Romero‐Sanz, Miguel Ángel Morcillo, Carlos Pérez‐Medina, Maria Angeles Moro, Gonzalo Villaverde, Jorge Rubio, Jose Fernandez‐Ferro, Manuel Desco, Fernando Herranz, Beatriz Salinas, Valentin Fuster, Marta Cortes‐Canteli   +22 more
wiley   +1 more source

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma. [PDF]

Hematology Am Soc Hematol Educ Program
Dima D, Banerjee R, Hansen DK.
europepmc   +1 more source

A Generalized Minimal PBPK-PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Spinosa P, Joslyn L, Ramanujan S, Gadkar K, Hosseini I.   +4 more
europepmc   +1 more source

Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies. [PDF]

J Immunother Cancer
Pan J, Yuan X, Yu H, Liu Z, Chen S, Zhu F, Shang Y, Hong S, Han X, Zhu Z, Jin T, Pan Y, Zhou S.   +12 more
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, Volume 78, Issue 7, Page 1393-1402, July 2026.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies. [PDF]

Front Med (Lausanne)
Alotaibi GS, Alsaeed A, Alahmadi M, Alamer A, Al Saleh AS, Barefah AS, Alhayli S, Mutahar EY, Abduljalil O, Kiwan H, Alhejazi A.   +10 more
europepmc   +1 more source

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B‐ALL After CAR‐T Therapy and HSCT: A Case Series

Cancer Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background Although inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B‐cell acute lymphoblastic leukemia (B‐ALL), data in the context of post chimeric antigen receptor (CAR)‐T cell therapy and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) relapse are lacking.
Honghu Li, Luxin Yang, Lizhen Liu, Xiaoyu Lai, Lixia Zhu, Kui Zhao, Qian Luo, He Huang, Yi Luo   +8 more
wiley   +1 more source